CYRX

Company Overview — What Does Cryoport, Inc. Do?

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee. Cryoport, Inc. (CYRX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jerrell W. Shelton and employs approximately 1,020 people, headquartered in IRVINE, Tennessee. With a market capitalization of $424M, CYRX is one of the notable companies in the Healthcare sector.

Cryoport, Inc. (CYRX) Stock Rating — Reduce (April 2026)

As of April 2026, Cryoport, Inc. receives a Reduce rating with a composite score of 32.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CYRX ranks #2,323 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cryoport, Inc. ranks #277 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CYRX Stock Price and 52-Week Range

Cryoport, Inc. (CYRX) currently trades at $9.67. The stock lost $0.09 (0.9%) in the most recent trading session. The 52-week high for CYRX is $11.45, which means the stock is currently trading -15.5% from its annual peak. The 52-week low is $4.63, putting the stock 108.9% above its annual trough. Recent trading volume was 467K shares, suggesting relatively thin trading activity.

Is CYRX Overvalued or Undervalued? — Valuation Analysis

Cryoport, Inc. (CYRX) carries a value factor score of 35/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 5.27x, compared to the Healthcare sector average of 23.63x — a discount of 78%. The price-to-book ratio stands at 0.91x, versus the sector average of 2.75x. The price-to-sales ratio is 2.45x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cryoport, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cryoport, Inc. Profitability — ROE, Margins, and Quality Score

Cryoport, Inc. (CYRX) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 17.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 11.4% versus the sector average of -33.1%.

On a margin basis, Cryoport, Inc. reports gross margins of 46.4%, compared to 71.5% for the sector. The operating margin is -23.9% (sector: -66.1%). Net profit margin stands at 47.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -23.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CYRX Debt, Balance Sheet, and Financial Health

Cryoport, Inc. has a debt-to-equity ratio of 52.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.17x, indicating strong short-term liquidity. Total debt on the balance sheet is $226M. Cash and equivalents stand at $256M.

CYRX has a beta of 1.40, meaning it is more volatile than the broader market — a $10,000 investment in CYRX would be expected to move 39.5% more than the S&P 500 on any given day. The stability factor score for Cryoport, Inc. is 40/100, reflecting average volatility within the normal range for its sector.

Cryoport, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cryoport, Inc. reported revenue of $187M and earnings per share (EPS) of $1.40. Net income for the quarter was $87M. Gross margin was 46.4%. Operating income came in at $-45M.

In FY 2025, Cryoport, Inc. reported revenue of $176M and earnings per share (EPS) of $1.40. Net income for the quarter was $78M. Gross margin was 47.1%. Revenue grew -22.9% year-over-year compared to FY 2024. Operating income came in at $-37M.

In Q3 2025, Cryoport, Inc. reported revenue of $44M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-7M. Gross margin was 48.2%. Revenue grew -21.9% year-over-year compared to Q3 2024. Operating income came in at $-10M.

In Q2 2025, Cryoport, Inc. reported revenue of $45M and earnings per share (EPS) of $2.05. Net income for the quarter was $105M. Gross margin was 47.0%. Revenue grew -21.1% year-over-year compared to Q2 2024. Operating income came in at $-10M.

Over the past 8 quarters, Cryoport, Inc. has demonstrated a growth trajectory, with revenue expanding from $58M to $187M. Investors analyzing CYRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CYRX Dividend Yield and Income Analysis

Cryoport, Inc. (CYRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CYRX Momentum and Technical Analysis Profile

Cryoport, Inc. (CYRX) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

CYRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cryoport, Inc. (CYRX) ranks #277 out of 838 stocks based on the Blank Capital composite score. This places CYRX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CYRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CYRX vs S&P 500 (SPY) comparison to assess how Cryoport, Inc. stacks up against the broader market across all factor dimensions.

CYRX Next Earnings Date

No upcoming earnings date has been announced for Cryoport, Inc. (CYRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CYRX? — Investment Thesis Summary

The quantitative profile for Cryoport, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 35/100 indicates premium valuation.

In summary, Cryoport, Inc. (CYRX) earns a Reduce rating with a composite score of 32.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CYRX stock.

Related Resources for CYRX Investors

Explore more research and tools: CYRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CYRX head-to-head with peers: CYRX vs AZN, CYRX vs SLGL, CYRX vs VMD.